Register for free to
view the full innovation profile.
Researchers in Professor Mehrdad Shamloo’s laboratory have developed novel small molecules that could potentially treat cardiovascular disease or CNS disorders.
About
Background: Researchers in Professor Mehrdad Shamloo’s laboratory have developed novel small molecules that could potentially treat cardiovascular disease, CNS disorders or other conditions by selectively targeting the β1-adrenoceptor (ADRB1). Adrenoceptors or adrenergic receptors are G-protein coupled receptors that are involved in a variety of physiological and metabolic processes including inotropic function of the cardiomyocytes, smooth muscle function, stress-related behavior, metabolic function, CNS disorders and inflammatory disorders. These new ligands can specifically activate the β1 subtype receptors. They could serve as important research tools to characterize those physiological processes in vitro and in vivo. Furthermore, the molecules could be developed as therapeutic agents for diseases that affect brain and heart function. We are asking parties interested in commercializing this technology to please contact Stanford OTL by Friday, June 16, 2017. Stage of Research: The inventors have shown that these compounds can increase heart rate and metabolism while reducing the blood pressure in animals. Further animal studies are ongoing. Applications: Therapeutic - treatment of cardiovascular disorders, neurodegenerative disorders and other conditions related to the adrenergic system Research - characterizing of physiological processes of heart and brain and using in vitro or in vivo models Advantages: Selective - novel compounds and selective compounds Related Web Links Shamloo Lab Innovators & Portfolio Andrew Evans Alam Jahangir Mehrdad Shamloo more technologies from Mehrdad Shamloo » Bitna Yi more technologies from Bitna Yi »